Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Leukemia Research |
Vol/bind | 38 |
Udgave nummer | 7 |
Sider (fra-til) | 816-821 |
Antal sider | 6 |
ISSN | 0145-2126 |
DOI | |
Status | Udgivet - jul. 2014 |
ID: 138381557